Company: MDCXW
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001062993-25-011673
Chunk: 18

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 18
---
 We filed an amendment to the Annual Report on Form 10-K with the SEC on April 30, 2025 to include the required executive compensation information and concurrently filed the supplemented Annual Report on Form 10-K on SEDAR+ at www.sedarplus.ca. We will furnish a copy of our Annual Report on Form 10-K (excluding exhibits, except those that are specifically requested) without charge to any Shareholder who so requests by writing to our Corporate Secretary at the address below under the heading in "" The Annual Report on Form 10-K, as amended, is also available free of charge on the "Investor Relations" section of our website at www.medicuspharma.com/investor-relations, on the SEC's website at www.sec.gov, and on SEDAR+ at www.sedarplus.ca.

By writing to us, Shareholders also may obtain, without charge, a copy of the Articles, code of conduct, Board Mandate and committee charters.

What if I have questions for the Company's transfer agent?

If you are a Shareholder of record and have questions concerning share certificates, ownership transfer or other matters relating to your share account, please contact our transfer agent at the following address:

<div align='center'>Odyssey Trust Company
Proxy Department,
702- 67 Yonge Street, Trader's Bank Building,
Toronto, Ontario, Canada
M5E 1J8
1- 888-290-1175</div>

How do I obtain additional copies of this proxy statement or voting materials?

If you need additional copies of this proxy statement or the proxy materials, please contact us at:

<div align='center'>Medicus Pharma Ltd.
Attn: Corporate Secretary
300 Conshohocken State Rd. Suite 200
W. Conshohocken, PA 19428
M5X 1A4
madesso@medicuspharma.com

OVERVIEW OF PROPOSALS TO BE VOTED ON</div>

Proposals 1, 2, 3, 4, 5 and 6 are included in this proxy statement at the direction of the Board. The Board unanimously recommends that you vote "" the appointment and remuneration of auditors in Proposal 1, "" the election of the nominees in Proposal 2, "" the Quorum Amendment in Proposal 3, "" the approval of the issuance of shares pursuant to the SEPA in accordance with the Nasdaq 20% Rule in Proposal 4,